innovation, inhouse research and development in biotechnology
Wuhan YZY Biopharma Co., Ltd. is a leading innovation-driven biotechnology company dedicated to developing bispecific antibody (BsAb)-based targeted and immune-oncology therapies to address the significant unmet medical needs of patients with cancer and age-related diseases. The mission is to discover and develop innovative drugs for healthier lives of patients.
Founded in 2010, YZYBIO has persisted in inhouse innovation, laid out and cultivated the field of bispecific antibodies, and strategically developed four innovative platforms, namely YBODY® platform, Check-BODY platform, Nano-YBODY™platform, and UVAX® platform. Based on the platforms, a series of products with advanced production technology, and stable product quality have been developed. Five of them are under clinical development in China, and five are in the discovery and pre-clinical stages.
-
4Innovative Platforms
-
80 %R&D Employees
-
77Patents and patent applications
(of which 30 have been granted, and 47 are under application)
Dr. Zhou Pengfei, the co-founder of the Group, was appointed as a director and the chief executive officer of the Company. He is responsible for the overall strategic planning of the Group and oversees the management of the business. Dr. Zhou obtained a bachelor’s degree in pediatrics in June 1989, and a master’s degree in pediatric surgery (oncology) in June 1994, from Tongji Medical University (同济医科大学) respectively. He also got a Doctor of Medicine from McMaster University in November 2005.
Dr. Zhou has over 33 years of experience in healthcare, drug research and team management, he worked for a number of leading enterprise, including Schering-Plough, Crown Bioscience International, acquired unique expertise in tumor biology and tumor immunotherapy.
Dr. Zhou now has served as a visiting professor at Tongji Medical College of Huazhong University of Science and Technology(华中科技大学同济医学院) as well as a visiting professor at Central South University (中南大学).
Dr. Yi Jizu currently serves as the senior vice president in quality control department, who is responsible for establishing quality management systems, analytical methods and quality control. Dr. Yi obtained a doctorate in biochemistry from Rutgers University. He was approved as one of the Wuhan High-Tech Development “3551” Talents, and a lifetime honorary member of the Chinese Antibody Society.
He served as an assistant professor at Mount Sinai School of Medicine of New York University, then served as a chief scientist at Becton, Dickinson and Company. He also worked in WuXi Biologics Co., Ltd. (无锡药明生物技术股份有限公司), which is a subsidiary of Wuxi Biologics (Cayman) Inc. (药明生物技术有限公司)
Dr. Yang Bin currently serves as the vice president of the process development and product manufacturing department of the Company, who is responsible for implementing the Group’s strategies and goals for technology development and product manufacturing. Dr. Yang obtained a bachelor’s degree in pharmacy from Wuhan University and obtained PhD in biomedicine from Jinan University (暨南大学).
Prior to joining YZY Biopharma, Dr. Yang served in various key positions at Shenzhen HEC Industrial Development Co., Ltd. and its subsidiaries (“HEC Group”), including the head of the monoclonal antibody department and deputy director of the biopharmaceuticals research institute.
Zhang Jing currently serves as the director of the R&D department, who is fully responsible for overseeing our operations and financial activities as well as leading the R&D department. Mr. Zhang joined the Group in January 2011 and successively served as a senior research assistant in the R&D department of the Company, a senior manager of the cell line development department of the Company and a director of the R&D department of the Company.
Prior to joining the Group, Mr. Zhang served as a research assistant at the Institute of Biophysics of the Chinese Academy of Science (中国科学院生物物理研究所) from August 2008 to December 2010.
Mr. Zhang received a bachelor's degree in biotechnology from the College of Life Sciences, Wuhan University (武汉大学) , and a master's degree in biochemistry and molecular biology from the Graduate School of Chinese Academy of Sciences (中国科学院研究生院) .
Dr. Huang Shaoyi, currently serves as the director of the clinical department, who is responsible for the academic support of the Company's clinical projects and developing policies and management processes related to clinical research.
Dr. Huang has extensive experience in clinical research and product development. He served as the deputy director of the medical oncology department of Wuhan YZY Medical Science and Technology Co., Ltd. (武汉友芝友医疗科技股份有限公司) from March 2014 to July 2020, where he was responsible for R&D and clinical work.
He obtained a bachelor's degree in biotechnology in June 2001 and a master's degree in microbiology in December 2004 from Wuhan University (武汉大学), respectively. In August 2013, he obtained a doctorate in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center.
-
Dr. Zhou Pengfei, the co-founder of the Group, was appointed as a director and the chief executive officer of the Company. He is responsible for the overall strategic planning of the Group and oversees the management of the business. Dr. Zhou obtained a bachelor’s degree in pediatrics in June 1989, and a master’s degree in pediatric surgery (oncology) in June 1994, from Tongji Medical University (同济医科大学) respectively. He also got a Doctor of Medicine from McMaster University in November 2005.
Dr. Zhou has over 33 years of experience in healthcare, drug research and team management, he worked for a number of leading enterprise, including Schering-Plough, Crown Bioscience International, acquired unique expertise in tumor biology and tumor immunotherapy.
Dr. Zhou now has served as a visiting professor at Tongji Medical College of Huazhong University of Science and Technology(华中科技大学同济医学院) as well as a visiting professor at Central South University (中南大学).
-
Dr. Yi Jizu currently serves as the senior vice president in quality control department, who is responsible for establishing quality management systems, analytical methods and quality control. Dr. Yi obtained a doctorate in biochemistry from Rutgers University. He was approved as one of the Wuhan High-Tech Development “3551” Talents, and a lifetime honorary member of the Chinese Antibody Society.
He served as an assistant professor at Mount Sinai School of Medicine of New York University, then served as a chief scientist at Becton, Dickinson and Company. He also worked in WuXi Biologics Co., Ltd. (无锡药明生物技术股份有限公司), which is a subsidiary of Wuxi Biologics (Cayman) Inc. (药明生物技术有限公司)
-
Dr. Yang Bin currently serves as the vice president of the process development and product manufacturing department of the Company, who is responsible for implementing the Group’s strategies and goals for technology development and product manufacturing. Dr. Yang obtained a bachelor’s degree in pharmacy from Wuhan University and obtained PhD in biomedicine from Jinan University (暨南大学).
Prior to joining YZY Biopharma, Dr. Yang served in various key positions at Shenzhen HEC Industrial Development Co., Ltd. and its subsidiaries (“HEC Group”), including the head of the monoclonal antibody department and deputy director of the biopharmaceuticals research institute.
-
Zhang Jing currently serves as the director of the R&D department, who is fully responsible for overseeing our operations and financial activities as well as leading the R&D department. Mr. Zhang joined the Group in January 2011 and successively served as a senior research assistant in the R&D department of the Company, a senior manager of the cell line development department of the Company and a director of the R&D department of the Company.
Prior to joining the Group, Mr. Zhang served as a research assistant at the Institute of Biophysics of the Chinese Academy of Science (中国科学院生物物理研究所) from August 2008 to December 2010.
Mr. Zhang received a bachelor's degree in biotechnology from the College of Life Sciences, Wuhan University (武汉大学) , and a master's degree in biochemistry and molecular biology from the Graduate School of Chinese Academy of Sciences (中国科学院研究生院) .
-
Dr. Huang Shaoyi, currently serves as the director of the clinical department, who is responsible for the academic support of the Company's clinical projects and developing policies and management processes related to clinical research.
Dr. Huang has extensive experience in clinical research and product development. He served as the deputy director of the medical oncology department of Wuhan YZY Medical Science and Technology Co., Ltd. (武汉友芝友医疗科技股份有限公司) from March 2014 to July 2020, where he was responsible for R&D and clinical work.
He obtained a bachelor's degree in biotechnology in June 2001 and a master's degree in microbiology in December 2004 from Wuhan University (武汉大学), respectively. In August 2013, he obtained a doctorate in cancer biology from the University of Texas Health Science Center at Houston and the University of Texas M.D. Anderson Cancer Center.
Patent protection for our YBODY® platform in U.S. expanded to cover 35 targets.
M701 became the second BsAb to file IND application in China.
Patent issued for the protection of M802 in China.
Patent issued for the protection of our YBODY® platform in CD3 and HER2 targets in U.S.
Completed Series B Financing(1) and raised an aggregate amount of approximately RMB168.7 million.
Obtained NMPA IND approval for our clinical investigation of Y150 in rrMM in China.
Obtained NMPA IND approval for our clinical investigation of Y2019 in China
Initiated a Phase II clinical trial for M701 in combination with systematic treatment for MA in patients with EpCAM-positive carcinomas in China.
The Company was converted into a joint stock limited company with its name changed to “Wuhan YZY Biopharma Co., Ltd.（武汉友芝友生物制药股份有限公司）
Obtained IND approval for a Phase Ib/II clinical trial of M701 for the treatment of MPE in China.
Entered into asset transfer agreement with CMS Opthalmology for Y400.
-
Phone：027-82668988 -
E-Mail：info@yzybio.com -
Postcode：430075 -
Address：Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China -
Fax：027-68788819 -
Business Development Contact：BD@yzybio.com
E-Mail：info@yzybio.com
Address：Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China
